Sorafenib (Nexavar)
. Draft fact sheet, awaiting Henry's approval. Items marked [check] must be verified before publishing.
← All drugs · Search the portal
Facts
| Topic | Fact | Source (access date) |
|---|---|---|
| First approval | US 1 Dec 2005 (kidney cancer); EU 19 Jul 2006; China import approval 2006 | Drugs@FDA via openFDA, https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA021923 (accessed 4 Nov 2026); EMA medicines report, https://www.ema.europa.eu/en/documents/report/medicines-output-medicines-report_en.xlsx (accessed 4 Nov 2026); market report https://pdf.marketpublishers.com/shcri/investigation-report-on-chinese-sorafenib-market-2018-2022.pdf (4 Nov 2026, secondary) |
| Mechanism | Kinase inhibitor acting on CRAF, BRAF, KIT, FLT-3, RET, VEGFR-1 to 3 and PDGFR-beta | openFDA label API, https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22NEXAVAR%22 (accessed 4 Nov 2026) |
| Use in osteosarcoma | Relapse; NCCN preferred second line (secondary source); Chinese guideline | NCCN via secondary source https://www.cancertherapyadvisor.com/ddi/bone-cancer-treatment-pharmacologic-management/ (accessed 31 Oct 2026; primary NCCN not opened); CSCO guideline and 2026 Chinese paediatric guideline, via /workspace/osteo-videos/level2/treatment_by_country.md (accessed 31 Oct 2026) |
| Combined with | Everolimus (Italian Sarcoma Group); compared with mifamurtide in Dragonfly | entries.json (portal export), sources opened 31 Oct to 3 Nov 2026 |
| Results | ISG phase 2 (35, over 14): 4-month PFS 46%, median PFS 4 months, OS 7 months, 3 partial responses (8%). With everolimus (38 adults): 6-month PFS 45%, target missed, 66% dose reductions or interruptions | doi:10.1093/annonc/mdr151; doi:10.1016/S1470-2045(14)71136-2 (3 Nov 2026) |
| Side effects | 20% or more: diarrhoea, tiredness, infection, hair loss, hand-foot skin reaction, rash, weight loss, lower appetite, nausea, abdominal pain, high blood pressure, bleeding | openFDA label API, https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22NEXAVAR%22 (accessed 4 Nov 2026) |
| Owner | Developed by Bayer with Onyx; Bayer markets Nexavar. Generic available in EU (Sorafenib Accord) | EMA medicines report, https://www.ema.europa.eu/en/documents/report/medicines-output-medicines-report_en.xlsx (accessed 4 Nov 2026); market report above |
| Regulatory | US, EU, UK, China: liver, kidney, thyroid cancers. Not osteosarcoma | entries.json (portal export), sources opened 31 Oct to 3 Nov 2026 |
Hypotheses and open points (not established fact)
- None recorded.